Hussein Tawbi
Overview
Explore the profile of Hussein Tawbi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
3139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lawson N, Ye L, Cho C, Zhao B, Mitchell T, Martin-Barrio I, et al.
medRxiv
. 2025 Mar;
PMID: 40061311
Highlights: is an early recurrent and targetable oncogene alteration in EAC-BM High T cell infiltration in -deleted tumor links to immunotherapy response Genomic instability of EAC-BM is marked by presence...
2.
Long G, Lipson E, Hodi F, Ascierto P, Larkin J, Lao C, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500452.
PMID: 40053890
No abstract available.
3.
Dumbrava E, Ben Haj Frej K, Sharon E, Tawbi H
Annu Rev Med
. 2024 Dec;
76(1):189-205.
PMID: 39656959
Immune checkpoint blockade targeting the novel targets of the lymphocyte activation gene 3 (LAG3) and the T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) has marked...
4.
Long G, Lipson E, Hodi F, Ascierto P, Larkin J, Lao C, et al.
J Clin Oncol
. 2024 Aug;
42(33):3926-3934.
PMID: 39137386
Purpose: Nivolumab plus relatlimab and nivolumab plus ipilimumab have been approved for advanced melanoma on the basis of the phase II/III RELATIVITY-047 and phase III CheckMate 067 trials, respectively. As...
5.
Saberian C, Milton D, Simon J, Amaria R, Diab A, McQuade J, et al.
Neurooncol Pract
. 2024 Jul;
11(4):452-463.
PMID: 39006528
Background: Melanoma leptomeningeal disease (LMD) has a poor prognosis. However, the management of patients with advanced melanoma has evolved with time, including those with LMD. We reviewed a large cohort...
6.
Le Rhun E, Weller M, Anders C, Larkin J, Li J, Moss N, et al.
Eur J Cancer
. 2024 Jul;
208:114202.
PMID: 38991283
With improved systemic treatment and prolonged survival even with metastatic disease, diagnosing, treating, and monitoring brain metastases has become a central topic in the care of patients with melanoma. Patients...
7.
Pellerino A, Davidson T, Bellur S, Ahluwalia M, Tawbi H, Ruda R, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893253
This review discusses the topic of prevention of brain metastases from the most frequent solid tumor types, i.e., lung cancer, breast cancer and melanoma. Within each tumor type, the risk...
8.
Turcios Escobar S, Yang R, Nelson K, Gershenwald J, Tawbi H, Aung P, et al.
J Cutan Pathol
. 2024 May;
51(9):644-648.
PMID: 38757469
During routine dermatologic examination, a 77-year-old male was noted to have a firm blue subcutaneous nodule on his right lateral upper back. His past medical history included metastatic melanoma of...
9.
Menzies A, Long G, Kohn A, Tawbi H, Weber J, Flaherty K, et al.
Neurooncol Adv
. 2024 May;
6(1):vdae033.
PMID: 38725995
Background: POLARIS (phase 2 [ph2]; NCT03911869) evaluated encorafenib (BRAF inhibitor) in combination with binimetinib (MEK1/2 inhibitor) in BRAF/MEK inhibitor-naïve patients with V600-mutant melanoma with asymptomatic brain metastases. Methods: The safety...
10.
Jackson-Carroll N, Johnson C, Tawbi H, Wang X, Whisenant M
Semin Oncol Nurs
. 2024 Jan;
40(1):151574.
PMID: 38220519
Objectives: The advent of immune checkpoint inhibitor (ICI) therapy has vastly improved outcomes for patients with advanced melanoma. However, the symptom burden and intensity with their impact on quality-of-life (HRQoL)...